Advanced Oncotherapy plc (AVO.L) Comparison with companies in other sectors?

Advanced Oncotherapy plc has a share price of 542.57M. You can analyze Advanced Oncotherapy plc (AVO.L) competitors across different market sectors through stock heatmaps.

What are AVO.L's NET and operating margins?

Advanced Oncotherapy plc (AVO.L) operating margin is around 0.00, and net profit margin is approximately 0.00 as of the latest reports.

In what way does AVO.L's earnings per share (EPS) trend reflect its financial momentum?

Advanced Oncotherapy plc (AVO.L) EPS is -0.07 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Advanced Oncotherapy plc is -0.25, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Advanced Oncotherapy plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Advanced Oncotherapy plc like P/E which is 0.00, P/B which is 0.00, and PEG which is 0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Advanced Oncotherapy plc

AVO.L•LSE

Healthcare

Medical - Devices

£1.75

£-0.18(-9.09%)

Fundamental Analysis of Advanced Oncotherapy plc (AVO.L)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.07

P/E Ratio

-0.25

ROE

Net Margin

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$9.50M

Shares OutstandingTotal number of shares issued

$542.57M

Book Value/ShareNet worth per share

Revenue/ShareAnnual revenue per share

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.07

Net MarginNet income as percentage of revenue

Operating MarginOperating income as percentage of revenue

ROEReturn on shareholders' equity

ROAReturn on total assets

ROCEReturn on capital employed

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for AVO.LFinancial Ratios Analysis details for AVO.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for AVO.LSector Benchmarking details for AVO.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Advanced Oncotherapy plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Advanced Oncotherapy plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Advanced Oncotherapy plc's unique business strengths and challenges.

Key Financial Metrics for Advanced Oncotherapy plc

For Advanced Oncotherapy plc, essential financial indicators include EPS -0.07, PE -0.25, and ROE -. These key ratios reveal insights into Advanced Oncotherapy plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Advanced Oncotherapy plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Advanced Oncotherapy plc

Metrics like Net Margin - and ROA - shed light on how well Advanced Oncotherapy plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Advanced Oncotherapy plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Advanced Oncotherapy plc

Using ratios such as P/B Ratio - and PEG Ratio -, investors can assess whether Advanced Oncotherapy plc is appropriately valued based on its financials and growth potential. These figures, combined with Advanced Oncotherapy plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Advanced Oncotherapy plc

Financial health indicators, such as Debt/Equity Ratio - and Cash Flow -, provide a snapshot of Advanced Oncotherapy plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Advanced Oncotherapy plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Advanced Oncotherapy plc

Investing in Advanced Oncotherapy plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Advanced Oncotherapy plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;